Sarcolipin is a novel regulator of cardiac sarcoplasmic reticulum Ca 2؉ ATPase 2a (SERCA2a) and is expressed abundantly in atria. In this study we investigated the physiological significance of sarcolipin in the heart by generating a mouse model deficient for sarcolipin. The sarcolipin-null mice do not show any developmental abnormalities or any cardiac pathology. The absence of sarcolipin does not modify the expression level of other Ca 2؉ handling proteins, in particular phospholamban, and its phosphorylation status. Calcium uptake studies revealed that, in the atria, ablation of sarcolipin resulted in an increase in the affinity of the SERCA pump for Ca 2؉ and the maximum velocity of Ca 2؉ uptake rates. An important finding is that ablation of sarcolipin resulted in an increase in atrial Ca 2؉ transient amplitudes, and this resulted in enhanced atrial contractility. Furthermore, atria from sarcolipinnull mice showed a blunted response to isoproterenol stimulation, implicating sarcolipin as a mediator of -adrenergic responses in atria. Our study documented that sarcolipin is a key regulator of SERCA2a in atria. Importantly, our data demonstrate the existence of distinct modulators for the SERCA pump in the atria and ventricles.atria ͉ calcium uptake ͉ sarcoplasmic reticulum Ca 2ϩ ATPase 2 S arcolipin (SLN), a low-molecular-weight protein (31 aa), is expressed in both cardiac and skeletal muscles (1-5). It colocalizes with sarcoplasmic reticulum (SR) Ca 2ϩ ATPase (SERCA) in the cardiac SR (3) and physically interacts with the SERCA pump (6). Amino acid composition and structural analysis have suggested that SLN and phospholamban (PLB) may belong to the same family of proteins with similar functions (1,(7)(8)(9). Consistent with the notion, in vitro studies have shown that SLN can inhibit the SERCA activity by decreasing the apparent Ca 2ϩ affinity of the pump (7, 10). Protein expression analyses have demonstrated that within the heart there are chamber-specific differences in the expression pattern of SLN and PLB (4). SLN is predominantly expressed in the atrial compartment, whereas PLB is abundant in the ventricles. In addition to atria, SLN is expressed in skeletal muscle tissues (4). SLN expression is regulated during cardiac and skeletal muscle development (2-4). Furthermore, SLN expression levels are altered in atria during cardiac pathology both in animal models (2, 4, 11-13) and in humans (14), suggesting that SLN levels may play an important role in maintaining atrial Ca 2ϩ homeostasis during cardiac pathophysiology.The importance of SLN as a regulator of the cardiac SERCA pump was recently demonstrated by using adenoviral gene transfer into adult rat ventricular myocytes (3) and transgenic overexpression of SLN in the heart (15-17). These studies suggest that overexpression of SLN into ventricular myocytes resulted in decreased rates of SR Ca 2ϩ uptake, Ca 2ϩ transient amplitude, and myocyte contractility. Overexpression of SLN in the PLB-null heart revealed that SLN can inhibit SERCA pump activity in...